Key result
Venous thromboembolism prophylaxis and tailored anticoagulant strategies are necessary for lung cancer patients due to their high risk of both VTE recurrence and major bleeding.
This editorial emphasizes the need for precision medicine in managing VTE in lung cancer patients, as their risk profile for recurrence versus bleeding differs significantly from other cancers.
Oncological patients have a higher risk for venous thromboembolism (VTE) (1,2), and also have an elevated risk of VTE recurrence and bleeding (3-5). Actually, guidelines in oncological patients with VTE recommend anticoagulant treatment, although these recommendations are the same, irrespectively of cancer and VTE location (6-9).
No takes yet. Share an insight, caveat, or question.
Jara‐Palomares et al. (2018) conducted an editorial in Venous thromboembolism associated with lung cancer. Venous thromboembolism prophylaxis was evaluated. Venous thromboembolism prophylaxis and tailored anticoagulant strategies are necessary for lung cancer patients due to their high risk of both VTE recurrence and major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: